The risk of breast cancer recurrence has been traditionally estimated using clinicopathological factors, including age, menopausal status, tumor size, tumor grade, lymph node involvement, and immunohistochemical biomarkers such as the proliferation index (Ki67), estrogen receptor, progesterone receptor, and HER2 amplification [6,7,8]. This evidence concerns the gene PGR and breast carcinoma.